Ubrelvy, ubrogepant
Named-patient access overview. Ubrelvy is coordinated by Reserve Meds for international patients through cross-border sourcing coordinated with your treating doctor.
This page is informational, not medical advice.
Ask about Ubrelvy
Tell us the medicine and your country. We reply within one business day. On WhatsApp we usually reply the same day.
About Ubrelvy
Ubrelvy (ubrogepant) is an oral, small-molecule calcitonin gene-related peptide (CGRP) receptor antagonist developed by Allergan and now marketed by AbbVie. The US Food and Drug Administration approved it in December 2019 for the acute treatment of migraine with or without aura in adults. It is taken as a single tablet at the onset of a migraine attack, with an optional repeat dose at least two hours later if symptoms persist or recur, up to a daily ceiling defined in the US label. Available strengths in the US are 50 mg and 100 mg tablets.
Case active and ready to skip the regulatory walkthrough? Ask about a medicine or WhatsApp us.
Ubrelvy belongs to the gepant class, a family of CGRP receptor antagonists that act on the neurovascular signalling thought to drive migraine pain. Unlike triptans, gepants do not cause direct vasoconstriction, which makes them clinically attractive for adults who have cardiovascular contraindications to triptans or who tolerate triptans poorly. Ubrelvy is approved specifically for acute treatment of an active attack; AbbVie's separate gepant Qulipta (atogepant) is approved for migraine prevention.
For international patients, Ubrelvy occupies a particular niche: it is a US-licensed brand that is not registered in many of the markets Reserve Meds serves. Patients in those markets sometimes pursue named-patient or personal-import pathways to obtain Ubrelvy under the care of their treating neurologist when local alternatives have failed or are contraindicated. Reserve Meds coordinates that sourcing from a US-licensed pharmaceutical wholesale partner.
How Reserve Meds coordinates Ubrelvy
- Patient or treating physician submits a named-patient request through our intake.
- The clinical team reviews appropriateness of Ubrelvy for the patient's migraine history, prior therapies, and destination country.
- The treating physician issues a prescription and a written clinical justification.
- Country-specific named-patient or personal-import documentation is prepared by our regulatory team.
- Ubrelvy is sourced from a US-licensed pharmaceutical wholesale partner with full serial-number traceability.
- The shipment is coordinated to the patient's physician, pharmacy, or home address, depending on the country pathway.
Throughout the case, a single case coordinator stays with the patient. There are no handoffs between teams, and the coordinator owns timeline, documentation, customs, and final delivery confirmation.
Clinical trials and expanded access
On 17 October 2026 we searched ClinicalTrials.gov, the clinical study registry of the US National Library of Medicine, for studies that list ubrogepant as an intervention. The search found studies that are recruiting or not yet recruiting. See the current list on ClinicalTrials.gov.
Whether a patient can join a trial or an expanded access program is decided by the study team or the manufacturer, together with the treating doctor. Reserve Meds does not run trials or supply investigational medicines. We can help you and your doctor read a listing and understand the route.
Access by country
Reserve Meds publishes a detailed country deep-dive for Ubrelvy in every market we coordinate. Each page below covers the destination-country regulatory pathway, how quotes work, indicative timelines, physician-credential requirements, and cold-chain handling. Tap any country to read the full deep-dive.
What patients typically ask about Ubrelvy
Is Ubrelvy a daily medicine or only for an attack? Ubrelvy is approved for acute treatment, meaning patients take it when a migraine starts, not on a daily schedule. For daily migraine prevention, neurologists may discuss different agents, including AbbVie's preventive gepant Qulipta or CGRP-targeting monoclonal antibodies.
Why might my neurologist suggest Ubrelvy rather than a triptan? Triptans cause vasoconstriction and are contraindicated for patients with established cardiovascular disease, uncontrolled hypertension, or prior stroke. Gepants like Ubrelvy do not act through vasoconstriction. Neurologists also reach for gepants when patients have not tolerated or not responded to triptans.
Is Ubrelvy registered in my country? In most markets Reserve Meds currently serves, Ubrelvy is not locally registered. The country deep-dives linked above describe the named-patient or personal-import route that applies in each jurisdiction, the documentation required, and the indicative timeline.
How is Ubrelvy shipped? Ubrelvy is an oral tablet at ambient temperature, so it does not require cold-chain handling. That keeps the logistics simpler than many of the biologics we coordinate, but the regulatory documentation and prescription validation steps still apply in every country.
What does a typical course cost? Every case gets a written custom quote before you commit, covering the medicine, Reserve Meds coordination, regulatory documentation, and shipping. Costs vary by destination because of import duties, VAT, and country-specific documentation. The per-country deep-dives publish indicative ranges; firm quotes are issued after a patient submits intake documents.
Clinical and safety notes
Ubrelvy is taken orally at the onset of a migraine attack. The US label permits a repeat dose at least two hours after the first dose if needed, with a maximum of 200 mg in 24 hours. Common adverse reactions in clinical trials included nausea and somnolence. Ubrelvy carries clinical considerations around concurrent use of strong CYP3A4 inhibitors and inducers, and the prescribing physician will review interactions with the patient's other medications. Reserve Meds does not replace the prescribing relationship; we coordinate access to a US-licensed medicine for a patient already under physician care.
Patients who experience severe headache features that differ from their usual migraine pattern, who develop new neurological symptoms, or who do not respond to acute therapy should contact their treating physician promptly. Reserve Meds is not an emergency service.
How Ubrelvy fits a migraine treatment plan
For most adults with episodic migraine, a treatment plan has two pillars: acute therapy to abort an attack once it starts, and, where attacks are frequent or disabling, preventive therapy taken on a regular schedule to reduce attack frequency and severity. Ubrelvy sits firmly in the acute pillar. It is taken at the first sign of a migraine attack, in a single oral dose, with the option of a repeat dose at least two hours later if the headache persists or recurs. A daily maximum applies. The acute role of a gepant is similar to that of a triptan, but with a different mechanism that does not constrict blood vessels.
That mechanism matters in two scenarios. First, patients who have established cardiovascular disease, uncontrolled hypertension, prior stroke, or other contraindications to triptans cannot safely use them. A gepant such as Ubrelvy can be a reasonable acute option in this population because it does not act through vasoconstriction. Second, some patients tolerate triptans poorly because of chest pressure, throat tightness, dizziness, or other class-related effects. A gepant offers a tolerability profile many of those patients find more workable. The treating neurologist will make the prescribing decision based on the patient's individual history.
For patients with frequent or chronic migraine who need a preventive strategy, the conversation moves to a different set of agents, including AbbVie's preventive gepant Qulipta (atogepant), the CGRP-targeting monoclonal antibodies, older oral preventives such as topiramate and propranolol, and onabotulinumtoxinA for chronic migraine. Reserve Meds coordinates several of these as well, in the markets where they are not locally available. Patients who think they may benefit from preventive therapy in addition to an acute agent should raise that question directly with their neurologist.
What is included in a Reserve Meds Ubrelvy case
A Reserve Meds case for Ubrelvy is more than a shipping arrangement. The named case coordinator confirms that the prescription, clinical justification, and patient identity documentation are complete before any procurement step begins. The regulatory team prepares country-specific named-patient or personal-import paperwork tailored to the destination, including translations where required. The procurement team places the order with a US-licensed pharmaceutical wholesale partner and confirms full serial-number traceability. The logistics team handles international shipping, customs documentation, and final-mile delivery, with proof-of-delivery returned to the case file. Throughout, the coordinator is the single point of contact for the patient and the treating physician. Patients do not chase a call centre; they message one person who already knows their case.
Start a request for Ubrelvy
Send us the medicine and your country. We reply within one business day with case-specific feasibility, timeline, and a formal quote.
Ask about a medicine Or message us on WhatsApp
Reserved for you.
Frequently asked questions
How can I get Ubrelvy if it is not approved or available in my country?
Reserve Meds coordinates US-sourced Ubrelvy for patients through a legal named-patient pathway, working with your treating doctor. Your treating physician provides the prescription and clinical justification; Reserve Meds prepares the named-patient documentation for your country and arranges DSCSA-compliant US sourcing and delivery to your physician or hospital pharmacy.
Can I access Ubrelvy through a named-patient import?
Often, yes. Named-patient access (sometimes called personal import) is the legal route we use for FDA-approved medicines such as Ubrelvy. It is different from compassionate use, which covers investigational medicines through the manufacturer's own program; we do not supply investigational medicines. Eligibility and paperwork depend on the regulator in your country, and Reserve Meds maps the specific pathway for each market it coordinates.
Do I need a prescription to access Ubrelvy through Reserve Meds?
Yes. Reserve Meds is not a pharmacy and does not prescribe. A valid prescription and clinical justification from your treating physician are required, and all clinical decisions remain with your physician.
How does Reserve Meds deliver Ubrelvy to a patient?
Medicines are supplied through a US-licensed pharmaceutical wholesale partner, and Reserve Meds coordinates delivery of Ubrelvy to your treating physician or hospital pharmacy, with appropriate handling for the product.
How long does it take, and what does Ubrelvy cost through Reserve Meds?
After a short intake, the clinical team responds within one business day with case-specific feasibility, an indicative timeline, and a formal written quote. Cost depends on the destination, the prescribed regimen, and the duration of therapy, and is confirmed in writing before anything proceeds.
How do I start a request for Ubrelvy?
Submit a 60-second intake through the Reserve Meds patient portal, or message our team on WhatsApp. We reply within one business day. On WhatsApp we usually reply the same day.